
Hormone Refractory Prostate Cancer Global Market Report 2025
Description
Hormone Refractory Prostate Cancer Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on hormone refractory prostate cancer market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies. Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes. Create regional and country strategies on the basis of local data and analysis. Identify growth segments for investment. Outperform competitors using forecast data and the drivers and trends shaping the market. Understand customers based on the latest market shares. Benchmark performance against key competitors. Suitable for supporting your internal and external presentations with reliable high quality data and analysis Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis. All data from the report will also be delivered in an excel dashboard format.
Description:
Where is the largest and fastest growing market for hormone refractory prostate cancer ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The hormone refractory prostate cancer market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market. The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development. The forecasts are made after considering the major factors currently impacting the market. These include: The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates. Market segmentations break down the market into sub markets. The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified. The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:1) By Treatment Type: Chemotherapy; Hormonal Therapy; Immunotherapy; Radiation Therapy; Surgery
2) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
3) By End-User: Hospitals; Ambulatory Surgical Centers; Specialty Clinics; Other End-Users
Subsegments:
1) By Chemotherapy: Docetaxel; Cabazitaxel; Mitoxantrone; Estramustin
2) By Hormonal Therapy: Anti-Androgens; CYP17 Inhibitors; LHRH Agonists; LHRH Antagonists
3) By Immunotherapy: Cancer Vaccines; Immune Checkpoint Inhibitors; Adoptive Cell Therapy
4) By Radiation Therapy: External Beam Radiation Therapy (EBRT); Brachytherapy; Radionuclide Therapy
5) By Surgery: Radical Prostatectomy; Orchiectomy; Transurethral Resection Of The Prostate (TURP)
Companies Mentioned: Pfizer Inc.; Johnson And Johnson; F. Hoffmann-La Roche Ltd.; Merck & Co. Inc.; AbbVie Inc.; Bayer AG; Sanofi S.A.; Bristol-Myers Squibb Company; Novartis AG; AstraZeneca plc; Takeda Pharmaceutical Company Limited; Eli Lilly and Company; Amgen Inc.; Astellas Pharma Inc.; Ipsen Pharma; Exelixis Inc.; Orion Corporation; Lantheus Holdings Inc.; Clovis Oncology Inc.; Telix Pharmaceuticals; Dendreon Pharmaceuticals LLC
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Please Note: Report will be updated with the latest data and delivered to you within 3-5 working days of order.
This report focuses on hormone refractory prostate cancer market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Description:
Where is the largest and fastest growing market for hormone refractory prostate cancer ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The hormone refractory prostate cancer market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
Scope
Markets Covered:1) By Treatment Type: Chemotherapy; Hormonal Therapy; Immunotherapy; Radiation Therapy; Surgery
2) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
3) By End-User: Hospitals; Ambulatory Surgical Centers; Specialty Clinics; Other End-Users
Subsegments:
1) By Chemotherapy: Docetaxel; Cabazitaxel; Mitoxantrone; Estramustin
2) By Hormonal Therapy: Anti-Androgens; CYP17 Inhibitors; LHRH Agonists; LHRH Antagonists
3) By Immunotherapy: Cancer Vaccines; Immune Checkpoint Inhibitors; Adoptive Cell Therapy
4) By Radiation Therapy: External Beam Radiation Therapy (EBRT); Brachytherapy; Radionuclide Therapy
5) By Surgery: Radical Prostatectomy; Orchiectomy; Transurethral Resection Of The Prostate (TURP)
Companies Mentioned: Pfizer Inc.; Johnson And Johnson; F. Hoffmann-La Roche Ltd.; Merck & Co. Inc.; AbbVie Inc.; Bayer AG; Sanofi S.A.; Bristol-Myers Squibb Company; Novartis AG; AstraZeneca plc; Takeda Pharmaceutical Company Limited; Eli Lilly and Company; Amgen Inc.; Astellas Pharma Inc.; Ipsen Pharma; Exelixis Inc.; Orion Corporation; Lantheus Holdings Inc.; Clovis Oncology Inc.; Telix Pharmaceuticals; Dendreon Pharmaceuticals LLC
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Please Note: Report will be updated with the latest data and delivered to you within 3-5 working days of order.
Table of Contents
250 Pages
- 1. Executive Summary
- 2. Hormone Refractory Prostate Cancer Market Characteristics
- 3. Hormone Refractory Prostate Cancer Market Trends And Strategies
- 4. Hormone Refractory Prostate Cancer Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
- 5. Global Hormone Refractory Prostate Cancer Growth Analysis And Strategic Analysis Framework
- 5.1. Global Hormone Refractory Prostate Cancer PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
- 5.2. Analysis Of End Use Industries
- 5.3. Global Hormone Refractory Prostate Cancer Market Growth Rate Analysis
- 5.4. Global Hormone Refractory Prostate Cancer Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
- 5.5. Global Hormone Refractory Prostate Cancer Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
- 5.6. Global Hormone Refractory Prostate Cancer Total Addressable Market (TAM)
- 6. Hormone Refractory Prostate Cancer Market Segmentation
- 6.1. Global Hormone Refractory Prostate Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Chemotherapy
- Hormonal Therapy
- Immunotherapy
- Radiation Therapy
- Surgery
- 6.2. Global Hormone Refractory Prostate Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- 6.3. Global Hormone Refractory Prostate Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Hospitals
- Ambulatory Surgical Centers
- Specialty Clinics
- Other End-Users
- 6.4. Global Hormone Refractory Prostate Cancer Market, Sub-Segmentation Of Chemotherapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Docetaxel
- Cabazitaxel
- Mitoxantrone
- Estramustine
- 6.5. Global Hormone Refractory Prostate Cancer Market, Sub-Segmentation Of Hormonal Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Anti-Androgens
- CYP17 Inhibitors
- LHRH Agonists
- LHRH Antagonists
- 6.6. Global Hormone Refractory Prostate Cancer Market, Sub-Segmentation Of Immunotherapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Cancer Vaccines
- Immune Checkpoint Inhibitors
- Adoptive Cell Therapy
- 6.7. Global Hormone Refractory Prostate Cancer Market, Sub-Segmentation Of Radiation Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- External Beam Radiation Therapy (EBRT)
- Brachytherapy
- Radionuclide Therapy
- 6.8. Global Hormone Refractory Prostate Cancer Market, Sub-Segmentation Of Surgery, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Radical Prostatectomy
- Orchiectomy
- Transurethral Resection Of The Prostate (TURP)
- 7. Hormone Refractory Prostate Cancer Market Regional And Country Analysis
- 7.1. Global Hormone Refractory Prostate Cancer Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 7.2. Global Hormone Refractory Prostate Cancer Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8. Asia-Pacific Hormone Refractory Prostate Cancer Market
- 8.1. Asia-Pacific Hormone Refractory Prostate Cancer Market Overview
- Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 8.2. Asia-Pacific Hormone Refractory Prostate Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.3. Asia-Pacific Hormone Refractory Prostate Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.4. Asia-Pacific Hormone Refractory Prostate Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 9. China Hormone Refractory Prostate Cancer Market
- 9.1. China Hormone Refractory Prostate Cancer Market Overview
- 9.2. China Hormone Refractory Prostate Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.3. China Hormone Refractory Prostate Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.4. China Hormone Refractory Prostate Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 10. India Hormone Refractory Prostate Cancer Market
- 10.1. India Hormone Refractory Prostate Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.2. India Hormone Refractory Prostate Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.3. India Hormone Refractory Prostate Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11. Japan Hormone Refractory Prostate Cancer Market
- 11.1. Japan Hormone Refractory Prostate Cancer Market Overview
- 11.2. Japan Hormone Refractory Prostate Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.3. Japan Hormone Refractory Prostate Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.4. Japan Hormone Refractory Prostate Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12. Australia Hormone Refractory Prostate Cancer Market
- 12.1. Australia Hormone Refractory Prostate Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.2. Australia Hormone Refractory Prostate Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.3. Australia Hormone Refractory Prostate Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13. Indonesia Hormone Refractory Prostate Cancer Market
- 13.1. Indonesia Hormone Refractory Prostate Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.2. Indonesia Hormone Refractory Prostate Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.3. Indonesia Hormone Refractory Prostate Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14. South Korea Hormone Refractory Prostate Cancer Market
- 14.1. South Korea Hormone Refractory Prostate Cancer Market Overview
- 14.2. South Korea Hormone Refractory Prostate Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.3. South Korea Hormone Refractory Prostate Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.4. South Korea Hormone Refractory Prostate Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15. Western Europe Hormone Refractory Prostate Cancer Market
- 15.1. Western Europe Hormone Refractory Prostate Cancer Market Overview
- 15.2. Western Europe Hormone Refractory Prostate Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.3. Western Europe Hormone Refractory Prostate Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.4. Western Europe Hormone Refractory Prostate Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16. UK Hormone Refractory Prostate Cancer Market
- 16.1. UK Hormone Refractory Prostate Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.2. UK Hormone Refractory Prostate Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.3. UK Hormone Refractory Prostate Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17. Germany Hormone Refractory Prostate Cancer Market
- 17.1. Germany Hormone Refractory Prostate Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.2. Germany Hormone Refractory Prostate Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.3. Germany Hormone Refractory Prostate Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18. France Hormone Refractory Prostate Cancer Market
- 18.1. France Hormone Refractory Prostate Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.2. France Hormone Refractory Prostate Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.3. France Hormone Refractory Prostate Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19. Italy Hormone Refractory Prostate Cancer Market
- 19.1. Italy Hormone Refractory Prostate Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.2. Italy Hormone Refractory Prostate Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.3. Italy Hormone Refractory Prostate Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20. Spain Hormone Refractory Prostate Cancer Market
- 20.1. Spain Hormone Refractory Prostate Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.2. Spain Hormone Refractory Prostate Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.3. Spain Hormone Refractory Prostate Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21. Eastern Europe Hormone Refractory Prostate Cancer Market
- 21.1. Eastern Europe Hormone Refractory Prostate Cancer Market Overview
- 21.2. Eastern Europe Hormone Refractory Prostate Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.3. Eastern Europe Hormone Refractory Prostate Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.4. Eastern Europe Hormone Refractory Prostate Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22. Russia Hormone Refractory Prostate Cancer Market
- 22.1. Russia Hormone Refractory Prostate Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.2. Russia Hormone Refractory Prostate Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.3. Russia Hormone Refractory Prostate Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23. North America Hormone Refractory Prostate Cancer Market
- 23.1. North America Hormone Refractory Prostate Cancer Market Overview
- 23.2. North America Hormone Refractory Prostate Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.3. North America Hormone Refractory Prostate Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.4. North America Hormone Refractory Prostate Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24. USA Hormone Refractory Prostate Cancer Market
- 24.1. USA Hormone Refractory Prostate Cancer Market Overview
- 24.2. USA Hormone Refractory Prostate Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.3. USA Hormone Refractory Prostate Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.4. USA Hormone Refractory Prostate Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25. Canada Hormone Refractory Prostate Cancer Market
- 25.1. Canada Hormone Refractory Prostate Cancer Market Overview
- 25.2. Canada Hormone Refractory Prostate Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.3. Canada Hormone Refractory Prostate Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.4. Canada Hormone Refractory Prostate Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26. South America Hormone Refractory Prostate Cancer Market
- 26.1. South America Hormone Refractory Prostate Cancer Market Overview
- 26.2. South America Hormone Refractory Prostate Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.3. South America Hormone Refractory Prostate Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.4. South America Hormone Refractory Prostate Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27. Brazil Hormone Refractory Prostate Cancer Market
- 27.1. Brazil Hormone Refractory Prostate Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.2. Brazil Hormone Refractory Prostate Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.3. Brazil Hormone Refractory Prostate Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28. Middle East Hormone Refractory Prostate Cancer Market
- 28.1. Middle East Hormone Refractory Prostate Cancer Market Overview
- 28.2. Middle East Hormone Refractory Prostate Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.3. Middle East Hormone Refractory Prostate Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.4. Middle East Hormone Refractory Prostate Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29. Africa Hormone Refractory Prostate Cancer Market
- 29.1. Africa Hormone Refractory Prostate Cancer Market Overview
- 29.2. Africa Hormone Refractory Prostate Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.3. Africa Hormone Refractory Prostate Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.4. Africa Hormone Refractory Prostate Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 30. Hormone Refractory Prostate Cancer Market Competitive Landscape And Company Profiles
- 30.1. Hormone Refractory Prostate Cancer Market Competitive Landscape
- 30.2. Hormone Refractory Prostate Cancer Market Company Profiles
- 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Johnson And Johnson Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
- 31. Hormone Refractory Prostate Cancer Market Other Major And Innovative Companies
- 31.1. Bayer AG
- 31.2. Sanofi S.A.
- 31.3. Bristol-Myers Squibb Company
- 31.4. Novartis AG
- 31.5. AstraZeneca plc
- 31.6. Takeda Pharmaceutical Company Limited
- 31.7. Eli Lilly and Company
- 31.8. Amgen Inc.
- 31.9. Astellas Pharma Inc.
- 31.10. Ipsen Pharma
- 31.11. Exelixis Inc.
- 31.12. Orion Corporation
- 31.13. Lantheus Holdings Inc.
- 31.14. Clovis Oncology Inc.
- 31.15. Telix Pharmaceuticals
- 32. Global Hormone Refractory Prostate Cancer Market Competitive Benchmarking And Dashboard
- 33. Key Mergers And Acquisitions In The Hormone Refractory Prostate Cancer Market
- 34. Recent Developments In The Hormone Refractory Prostate Cancer Market
- 35. Hormone Refractory Prostate Cancer Market High Potential Countries, Segments and Strategies
- 35.1 Hormone Refractory Prostate Cancer Market In 2029 - Countries Offering Most New Opportunities
- 35.2 Hormone Refractory Prostate Cancer Market In 2029 - Segments Offering Most New Opportunities
- 35.3 Hormone Refractory Prostate Cancer Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies
- 36. Appendix
- 36.1. Abbreviations
- 36.2. Currencies
- 36.3. Historic And Forecast Inflation Rates
- 36.4. Research Inquiries
- 36.5. The Business Research Company
- 36.6. Copyright And Disclaimer
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.